Millennial urologists appear to have developed strong opinions on health policy as reflected by their recent social media activity, observes urologist Alan L. Kaplan, MD.

"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.

In a groundbreaking cross-border collaboration, Cleveland Clinic urologists recently completed the world's first remotely performed robot-assisted high-intensity focused ultrasound (HIFU) focal ...

Welcome to Urology Times’ ® monthly FDA update! June was a busy month for urological regulatory news, featuring new approvals for prostate cancer, bladder cancer, benign prostatic hyperplasia (BPH), ...

Leflutrozole, an aromatase inhibitor, is being tested in a phase 2 trial for male infertility due to low testosterone levels. The trial will enroll 200 patients, assessing leflutrozole's impact on ...

Gedatolisib and darolutamide combination showed a 66% 6-month rPFS in mCRPC patients, indicating promising preliminary efficacy. Safety data revealed no treatment discontinuations or dose reductions ...

The first patient has been dosed in the phase 2 SURF302 trial (NCT06995677), assessing the safety and efficacy of TYRA-300 in patients with FGFR3 -altered low-grade, intermediate-risk non–muscle ...

Justin Dubin, MD, touches on the current landscape of men’s health, with a specific focus on the advent of AI.

In a recent interview with Urology Times®, Kevin T. McVary, MD, FACS, discussed the short-term safety and efficacy of the Rezūm System for larger prostates, referencing a meta-analysis in Urology that ...

Johnson & Johnson has submitted an application to the European Medicine’s Agency (EMA) seeking an expanded indication for niraparib and abiraterone acetate (Akeega) with prednisone or prednisolone to ...

Panelists discuss the expanding clinical development of cretostimogene across multiple NMIBC populations and treatment strategies, highlighting ongoing trials exploring its use as monotherapy and in ...

Panelists discuss how molecular imaging could transform metastatic kidney cancer management by helping determine whether cytoreductive nephrectomy is necessary and assessing treatment response to ...